Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02788214 · ClinicalTrials.gov registry record

Helicobacter Pylori Genome Project (HpGP)

A clinical trial, sponsored by National Cancer Institute (NCI).

Terminated
Registry status
1,000
Enrollment target

NCT02788214: Clinical Trial study, sponsored by National Cancer Institute (NCI).

NCT02788214 is a clinical trial that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 1,000 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02788214 was terminated before completion, sponsored by National Cancer Institute (NCI).

TERMINATED
Registry status
1,000 participants
Enrollment target

Study Summary

Helicobacter pylori is a common bacterial infection. It can lead to severe stomach problems, including stomach cancer. Researchers want to look at samples of the bacteria. These H. pylori strains will be taken from chronically infected people. They want to identify the genetic and epigenetic differences in H. pylori strains. This could help predict which people who get infected with the bacteria will get stomach cancer. This could lead to the cancer being detected earlier. It could also mean less people get stomach cancer. Objectives: To study genetic variations of H. pylori strains based on samples from chronically infected people. To identify the features of strains that might lead to severe stomach problems or stomach cancer. Eligibility: People ages 30-70 years who need an upper endoscopy or who were recently diagnosed with stomach cancer Design: Participants will be screened by the doctor who does their procedure and a study nurse. Participants who have endoscopy will have \~6 biopsies removed. These are tissue samples. They are about the size of a grain of rice. Participants will allow the study team to access reports from their stomach exam. Participants with stomach cancer will donate some of the tissue that will be removed during their clinical care. They will allow the study team to access reports of their surgery. They will also allow them to access the microscope slides of their stomach.

Primary Outcome

genome and methylome

Trial Details

FieldValue
Enrollment Target 1,000 participants
Start Date 2016-07-27
Est. Completion 2020-05-15
National Cancer Institute (NCI)

3,257 total trials

Why NCT02788214 stopped before completion

NCT02788214 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 0 interventions.

NCT02788214 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02788214 about?

NCT02788214 is a clinical study titled "Helicobacter Pylori Genome Project (HpGP)". Helicobacter pylori is a common bacterial infection. It can lead to severe stomach problems, including stomach cancer. Researchers want to look at samples of the bacteria. These H. pylori strains will be taken from chronically infected people. They want to identify the genetic and epigenetic differe...

What is the current status of trial NCT02788214?

This trial is currently terminated. The enrollment target is 1,000 participants. The study started on 2016-07-27. Estimated completion is 2020-05-15.

Who is sponsoring clinical trial NCT02788214?

This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00018044 · 1,000 participants

    Study of Mycobacterial Infections

  • NCT01036581 · 1,000 participants · NA

    Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging

  • NCT01192048 · 1,000 participants

    Genetics of Congenital Heart Disease

  • NCT01553214 · 1,000 participants · Phase 4

    Improving White Blood Cell Collection From Healthy Donors

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02788214, the US trial registry maintained by the National Library of Medicine. NCT02788214 (large enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.